➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Medtronic
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,967,208


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,967,208 protect, and when does it expire?

Patent 6,967,208 protects ELIQUIS and is included in one NDA.

This patent has seventy-four patent family members in thirty-six countries.

Summary for Patent: 6,967,208
Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s): Pinto; Donald J. P. (Churchville, PA), Quan; Mimi L. (Yardley, PA), Orwat; Michael J. (New Hope, PA), Li; Yun-Long (Wilmington, DE), Han; Wei (Yardley, PA), Qiao; Jennifer X. (Princeton, NJ), Lam; Patrick Y. S. (Chadds Ford, PA), Koch; Stephanie L. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:10/245,122
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,967,208
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,967,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM ⤷  Try it Free
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ⤷  Try it Free
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF PULMONARY EMBOLISM (PE) ⤷  Try it Free
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) ⤷  Try it Free
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM ⤷  Try it Free
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,967,208

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037092 ⤷  Try it Free
Argentina 067965 ⤷  Try it Free
Austria 439360 ⤷  Try it Free
Austria 544750 ⤷  Try it Free
Australia 2002341693 ⤷  Try it Free
Australia 2008207537 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Baxter
Medtronic
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.